Form 4: Humacyte Director Brady W. Dougan Reports Share Purchase by Spouse

Director Brady W. Dougan reports a purchase of Humacyte, Inc. common stock by his spouse, along with adjustments to his beneficial ownership.

Summary

• On June 4, 2024, Brady W. Dougan, a director of Humacyte, Inc., filed a Form 4 disclosing a purchase of 2,362 shares of common stock by his spouse at a weighted average price of $6.35 per share.
• The purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934 against a sale by Ayabudge LLC, an entity controlled by Dougan, of 93,213 shares on May 31, 2024.
• Dougan's spouse paid Humacyte $7,015.79, representing the profit realized from the purchase.
• Following the transaction, Dougan's direct holdings include 510,161 shares, while indirect holdings include 240,832 shares held by his spouse, 1,148,240 shares held by The Niklason Living Trust, and 5,189,288 shares held by Ayabudge LLC.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, indicating neutral sentiment. It reports a transaction and compliance measure, without expressing any positive or negative outlook.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, ensuring transparency and compliance with securities regulations.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for corporate insiders in the US, similar to filings required of directors and officers in other developed markets.
• The transactions reported are relatively small in scale compared to overall trading volumes of similar companies, but are still subject to scrutiny to ensure compliance with insider trading regulations.
• The payment to the issuer to cover profits from the matchable transaction is a standard remedy to avoid potential violations of Section 16(b) of the Securities Exchange Act.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it involves a small number of shares.
• The payment to the issuer benefits the company by recovering profits from a matchable transaction.

Key Dates